A phase IV, controlled, open-label, single-center study in adolescents and adults: evaluation of immunogenicity and safety of the first booster immunization with Novartis' TBE vaccine for adults in participants of study V48P7 and long-term evaluation of immunogenicity up to 5 years after first booster immunization.
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2014
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 01 Nov 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.